TPX-100 Delays Pathological Changes of Bone in Osteoarthritis of the Knee in phase 2 trial

OrthoTrophix, Inc. announced new analyses from a Phase 2 study of TPX-100, the company’s osteoarthritis (OA) drug candidate. The new results indicate slowing or halting of pathological bone shape changes, findings that support structural disease modification by TPX-100 treatment. Previous analysis demonstrated robust and statistically significant clinical benefits of the drug in moderate to severe knee OA. Study TPX-100-5, entitled “Longitudinal Evaluation of Periarticular Bone Area and 3D Shape in...

Promising Treatment for Periodontitis Gum Regeneration tested at Tohoku University

Researchers have designed a safer, faster and cheaper cell-based regenerative therapy approach for the treatment of one of the most common human dental diseases, namely periodontitis. A destructive and painful condition that is marked by inflammation and subsequent loss of the gums and the supporting structures of the teeth, periodontitis is caused by bacteria that trigger inflammation of the gums that surround teeth. The proposed therapy design promises to address periodontitis without the shortcomings and limitations of...

Keck School of Medicine Discovers that Sox9+ messenger cells orchestrate large-scale skeletal regeneration

How do bones heal, and how could they heal better? The answer to these questions may lie in a newly discovered population of “messenger” cells, according to a recent USC Stem Cell study published in the journal eLife. “With nearly half a million patients in the U.S experiencing failed bone repair every year, stimulating these ‘messengers’ and other key cell types could accelerate repair and prevent non-unions,” said corresponding author Francesca...